Antibody-peptide-MHC fusion conjugates target non-cognate T cells to kill tumour cells. - Wikidata - wikimedia - TriplyDB

Antibody-peptide-MHC fusion conjugates target non-cognate T cells to kill tumour cells.

Antibody-peptide-MHC fusion conjugates target non-cognate T cells to kill tumour cells.

http://www.wikidata.org/entity/Q37407181

about

Antigen-specific T cell Redirectors: a nanoparticle based approach for redirecting T cells.Alpha-Galactosylceramide/CD1d-Antibody Fusion Proteins Redirect Invariant Natural Killer T Cell Immunity to Solid Tumors and Promote Prolonged Therapeutic Responses.

P2860

Q37708824-5DE00862-0883-4205-993B-A8527CCD3FD3 Q44851304-03A557F5-919F-444F-A627-FDA070B5BB18

P2860

Antibody-peptide-MHC fusion conjugates target non-cognate T cells to kill tumour cells.

http://www.wikidata.org/entity/Q37407181

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 19 April 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Antibody-peptide-MHC fusion conjugates target non-cognate T cells to kill tumour cells.

@en

Antibody-peptide-MHC fusion conjugates target non-cognate T cells to kill tumour cells.

@nl

type

label

Antibody-peptide-MHC fusion conjugates target non-cognate T cells to kill tumour cells.

@en

Antibody-peptide-MHC fusion conjugates target non-cognate T cells to kill tumour cells.

@nl

prefLabel

Antibody-peptide-MHC fusion conjugates target non-cognate T cells to kill tumour cells.

@en

Antibody-peptide-MHC fusion conjugates target non-cognate T cells to kill tumour cells.

@nl

P1433

Q37407181-2EE26D7C-DC65-4118-B44E-9A91EB75C71D

P1476

Q37407181-0F8D17FC-21F3-4EE2-BB56-95FE2E443A2D

P2093

Q37407181-0DF1367C-EFFF-47FF-B654-5DE5E0589C13

Q37407181-0E3D530D-129D-4CA6-9C50-EF304D1E9C03

Q37407181-1CCE1940-681A-49F4-9B49-3B98F8A8C031

Q37407181-4B33AE1C-3EB0-4168-B5EF-8A426DF8C44E

Q37407181-4EC6384B-826F-4C50-B900-6733828E2A18

Q37407181-E5E19EAE-35D7-4962-BD27-AE31E26AFFD3

P2860

Q37407181-0AD8A294-9880-4321-AC67-C57A09B50BC2

Q37407181-0C0E74DB-E799-4B21-8415-A1EC22FCC17F

Q37407181-0C5B946B-E751-4502-822D-68F3D6FAD8D4

Q37407181-14F3C9CB-2CE0-4EE4-AD88-7BB90F0BEDE9

Q37407181-1DDFA2BE-7758-4F94-A871-A02062E837DB

Q37407181-33A0C019-5513-4867-B2A6-CBC812465C68

Q37407181-44F059B9-4CE0-4398-BB1E-3AB12B371AB3

Q37407181-570B6CEC-481A-4B23-9A12-A9BD299FA46D

Q37407181-5BD765C1-04FC-4A67-A200-2264EFB76517

Q37407181-734A176D-FB4B-4897-B6C6-1F50A36DC680

P2888

Q37407181-C1B1C7A8-759F-45EA-9D91-FD40F636B171

P304

Q37407181-D99E05D1-CB3C-45A1-95F5-C918EA9DF4C5

P31

Q37407181-A4FCF57D-F024-4312-AA44-C3E18DBBE880

P356

Q37407181-644FDEB4-4BBD-4AFE-B2C8-EEA457B0B39A

P433

Q37407181-2B4EC6FB-5B60-4DA8-9240-A49B75904835

P478

Q37407181-037237D2-8C3E-47CA-84D5-641D51579EEC

P50

Q37407181-AEA047D2-32F0-474A-B9FA-37E56EFD35C1

Q37407181-B847B6B2-D0B0-4605-A5F5-026E9384BEE4

P577

Q37407181-A9D3FF30-8D3E-49DD-B7C5-FDD668F296B5

P5875

Q37407181-BAE7F632-39A4-4D91-A1B9-A054E8A6016E

P698

Q37407181-D0C9CBBA-6083-4897-A030-17B66431BA8D

P932

Q37407181-E11041DD-2ACF-4535-A534-F42539ADE637

P356

S00262-013-1408-8

P1433

Cancer Immunology, Immunotherapy

P1476

Antibody-peptide-MHC fusion conjugates target non-cognate T cells to kill tumour cells.

@en

P2093

Angela D Hamblin

http://www.w3.org/2001/XMLSchema#string

Leon R Douglas

http://www.w3.org/2001/XMLSchema#string

Martin J Glennie

http://www.w3.org/2001/XMLSchema#string

Peter W M Johnson

http://www.w3.org/2001/XMLSchema#string

Ruth R French

http://www.w3.org/2001/XMLSchema#string

Ted H Hansen

http://www.w3.org/2001/XMLSchema#string

P2860

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

Cancer regression in patients after transfer of genetically engineered lymphocytes

Phenotypic characterization of human colorectal cancer stem cells

Surface-anchored monomeric agonist pMHCs alone trigger TCR with high sensitivity

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

P2888

s00262-013-1408-8

P304

1093-1105

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-013-1408-8

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

62

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-04-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236252750

http://www.w3.org/2001/XMLSchema#string

P698

23604105

http://www.w3.org/2001/XMLSchema#string

P932

3869625

http://www.w3.org/2001/XMLSchema#string